Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Neurocrine Biosciences Inc (NBIX) Com Stk NPV (CDI)

Sell:$104.11 Buy:$116.80 Change: $0.84 (0.75%)
NASDAQ:0.20%
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Sell:$104.11
Buy:$116.80
Change: $0.84 (0.75%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Sell:$104.11
Buy:$116.80
Change: $0.84 (0.75%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.

Contact details

Address:
12780 El Camino Real
SAN DIEGO
92130-2042
United States
Telephone:
+1 (858) 6177600
Website:
www.neurocrine.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NBIX
ISIN:
US64125C1099
Market cap:
$10.43 billion
Shares in issue:
92.09 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • William Rastetter
    Independent Chairman of the Board
  • Kevin Gorman
    Chief Executive Officer, Director
  • Matthew Abernethy
    Chief Financial Officer
  • Eric Benevich
    Chief Commercial Officer
  • David Boyer
    Chief Corporate Affairs Officer
  • Haig Bozigian
    Chief Development Officer
  • Kyle Gano
    Chief Business Development Officer
  • Dimitri Grigoriadis
    Chief Research Officer
  • Malcolm Lloyd-Smith
    Chief Regulatory Officer
  • Eiry Roberts
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.